MedaSorb's Blockbuster Product Could be Commercialized This Year
In a recent interview, MedaSorb Technology Corporation's (OTC: MSBT) Chief Executive Officer, Dr. Phillip Chan, said in a recent interview that if European trials for its flagship product CytoSorb™ in Germany prove as successful as expected, the Company could receive EU approval and begin commercialization late this year. Read the entire news here.
*Text from tradingmarkets.com
Thursday, February 4, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment